In this study, it has been hypothesized that the combination of a dual blocker of IGF1R/IR, OSI-906, with the mTORi SIR, would potentiate the antitumor effects of SIR used as a single agent in HCC cells, because down-regulating AKT and MAPK survival pathway upstream with OSI-906, the resistance to mTORi, induced by mechanisms of escape, can be overcome. This evidence concerns the gene AKT1 and hepatocellular carcinoma.